The European Journal of Emergency Medicine
The European Journal of Emergency Medicine is the official publication of the European Society for Emergency Medicine. This journal focuses on supporting the emergency medicine community across Europe and aims to enhance the standards of training, diagnosis, and patient care in this fast-evolving area of medicine.
Outlet metrics
Global
N/A
Country
N/A
Category
N/A
Articles
-
5 days ago |
journals.lww.com | Catlin Nalley
By Catlin NalleyThe Phase III SERENA-6 trial demonstrated that switching to camizestrant in combination with a CDK4/6 inhibitor—guided by the emergence of an ESR1 mutation (ESR1m) during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy—led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) for patients with hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer.
-
2 months ago |
journals.lww.com | Dawn Fallik
Tolebrutinib, a brain-penetrant Bruton tyrosine (BTK) inhibitor, significantly slowed disability progression in multiple sclerosis, according to research from two different phase 3 trials presented at the AAN Annual Meeting in San Diego.
-
2 months ago |
journals.lww.com | Gina Shaw
Use of over-the-counter (OTC) analgesics—including both acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs)—after a traumatic brain injury (TBI) was significantly associated with improved concussion symptoms and recovery, according to new data presented at the AAN Annual Meeting in San Diego. The prospective cohort study of National Collegiate Athletic Association (NCAA) and military cadets also found that the OTC drugs led to a quicker return to play.
-
2 months ago |
journals.lww.com | Gina Shaw
Modern hormonal contraceptives, which contain substantially lower doses of estrogen compared with earlier-generation high-dose combined oral contraceptives, are not associated with an increased risk of stroke and other vascular events in women with migraine, both with and without aura, according to findings presented at the AAN Annual Meeting in San Diego. The large study used data from a nationwide de-identified electronic health record database.
-
2 months ago |
journals.lww.com | Gina Shaw
Inebilizumab (Uplizna), a monoclonal antibody targeting CD19+ B-cells, significantly improves disease severity in patients with generalized myasthenia gravis (MG), according to new findings from the MINT phase 3 clinical trial presented at the AAN Annual Meeting in San Diego.
The European Journal of Emergency Medicine journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →